

Recent developments making IBA Proton Therapy System more accessible

Founded in 1986, IBA mission is to Protect, Enhance and Save Lives. At IBA, we are a passionate team of professionals dedicated to developing leading-edge technologies to fight cancer, a disease that affects us all, either directly or indirectly.

With its cyclotrons for PET & SPECT radio-tracers, Synthera labeling modules and the Integralab concept, IBA provides all the expertise needed to create your own radio-pharmacy and produce radiopharmaceuticals for Nuclear Medicine Departments, thus providing our contribution in the diagnosis of cancer <http://www.iba-molecular.com>.

More precise dose delivery, fewer side effects, better results — IBA Proton Therapy is changing the way cancer is treated. As the worldwide leader in developing Proton Therapy systems, our groundbreaking innovations and flexible solutions are making Proton Therapy a reality for more doctors, more communities and more patients.

To date, IBA has been selected to install 24 proton therapy centers of which 11 are currently treating patients and 9 are under installation or construction. IBA's installations represent more than half of the clinically based proton therapy facilities in the world. The IBA PROTEUS-230 concept, already sold, installed and in operation throughout the world, including Essen, Orsay, Trento, Prague, Dresden, Krakow, Upsalla and Dimitrovgrad is offering to Radiotherapy Departments the most

experienced system commercially available in term of patient treatments with protons.

The system is delivered with different treatment rooms like: fixed beam room, eye line, inclined beam line and 360° Gantry, offering maximum flexibility to the clinicians. The Universel Nozzle (four beam modes available, including scattering and scanning modes) and the Pencil Beam Scanning Nozzle (IMPT) are proposed to equip the treatment room.

With the development of a CBCT solution, IBA proposes to the market an integrated solution in which 3D patient imaging at the treatment point will be available.

Finally, IBA announced at last ASTRO in October 2010, the development of a more compact system, named Proteus ONE™*, built on a new supra-conductive synchrocyclotron and a compact gantry. IBA engineers and designers have spent more than a year devising Proteus ONE™*, a smaller, more costeffective Proton Therapy system. The new design also simplifies deployment of multi-room facilities, requires less land and leaves a smaller footprint.

<http://www.iba-protontherapy.com/proteus-one>

Claude Dupont
VP Integration & Sales, IBA Sales & Marketing
e-mail: claudio.dupont@iba-group.com